Cannabis lowered some lipid risks but raised kidney concerns

Safety and Efficacy Assessment of Cannabis Plant Compared to Atorvastatin for Lipid Lowering in Diabetic and Obese Wistar Male Rats.

Life (Basel, Switzerland) • • Highly Relevant
🤖

AI Summary

This small animal study compared cannabis plant extract with atorvastatin in 14 obese, diabetic male rats over 30 days. Both treatments improved some atherogenic indices, which estimate cardiovascular risk, but atorvastatin produced the stronger lipid-related effects. Cannabis extract modestly improved the overall lipid profile, while it did not change LDL cholesterol; the abstract does not establish that cannabis is an effective replacement for statins.

The safety findings were mixed. Liver enzymes rose with atorvastatin but remained virtually unchanged with cannabis extract, suggesting less apparent liver impact in this model. However, serum creatinine increased with cannabis treatment, indicating a potential renal safety concern. The researchers also cite possible neurological and addiction-related consequences, concluding that these issues limit the treatment’s applicability to humans and require further study.

💡 Key Findings

1
In obese, diabetic rats, cannabis plant extract modestly improved the lipid profile and atherogenic indices, but generally less effectively than atorvastatin.
Moderate
50%
2
Cannabis extract did not change LDL cholesterol, while atorvastatin increased HDL cholesterol more strongly.
Moderate
50%
3
Liver enzymes remained virtually unchanged with cannabis extract but increased with atorvastatin, indicating less apparent liver impact from cannabis in this animal model.
Moderate
50%
4
Serum creatinine increased with cannabis treatment, raising a potential kidney-safety concern that limits its applicability to humans.
Moderate
55%
5
The authors conclude that possible renal, neurological, and addiction-related risks require further investigation before cannabis could be considered for lipid lowering.
Moderate
45%

📄 Original Abstract

Introduction. Statins' established cardiovascular benefits are often undermined by hepatic adverse effects in obese diabetic patients with suspected non-alcoholic fatty liver disease. We evaluated whether cannabis plant treatment is a safe and effective alternative to atorvastatin in a metabolically challenged rodent model. Methods. Fourteen obese and diabetic Wistar rats received either atorvastatin for 30 days or cannabis plant extract for 30 days. Main outcome: lipid profile; secondary outcomes: renal function, glycemia and endothelial health assessed through atherogenic indices. Safety was assessed using plasma liver enzyme concentrations. Results. Baseline biochemical profiles were similar between groups. Atorvastatin increased HDL-Col more than cannabis plant (MD: 44.3; IQR [33, 57.5] mg/dL, Hedges' g 2.713 vs. MD: 14.3; IQR [14, 17] mg/dL, Hedges' g 5.049), and cannabis plant did not change LDL-Col. Atherogenic index of plasma and Castelli Risk Index 1 improved with both interventions, more so with atorvastatin. Liver enzymes increased with atorvastatin (ALAT, MD: 15.9; IQR [12.5, 19.5] U/L; ASAT, MD: 33; IQR [26.5, 38] U/L) but remained virtually unchanged with cannabis. Serum creatinine increased with cannabis plant, with moderate effect size (Hedges' g 0.798), but negligibly with statins (Hedges' g 0.122). Conclusions. Cannabis plant extract modestly improved the lipid profile and atherogenic indices, with differences often not exceeding the change in control groups. Despite apparent liver safety, the undesired renal and neurological consequences limit applicability in humans. Further studies should prioritize addiction development and renal function.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.